Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Batea Oncology General Information
Batea Oncology has developed GlioHook, a Class III medical device designed to capture and concentrate residual glioblastoma cells after surgical resection. In animal models, GlioHook increased survival by 50% compared to radiotherapy alone. The company is currently completing regulatory preclinical studies and aims to begin a Phase I clinical trial in 2025 at three Spanish hospitals[1][2].
Contact Information
Website
Primary Industry
Implantable Medical Devices
Corporate Office
Santiago de Compostela, Galicia
Spain
Spain
Drug Pipeline
GlioHook
Pre-clinicalKey Partnerships
Asociación Española Contra el Cáncer – AECC IMPACTO program funding/support[3], Clúster Tecnolóxico Empresarial das Ciencias da Vida – Bioga member/partner[2], Support from Xunta de Galicia/Xesgalicia for financing and business development[4]
Batea Oncology Funding
No funding data available
To view Batea Oncology's complete valuation and funding history, request access »